8-K: Pliant Therapeutics Announces Positive Interim Data for Bexotegrast in Primary Sclerosing Cholangitis Trial

Pliant Therapeutics reports positive 12-week interim results from its Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis, showing the drug was well-tolerated and demonstrated antifibrotic activity.

Summary

• Pliant Therapeutics announced positive 12-week interim data from the 320 mg dose group of its INTEGRIS-PSC Phase 2a clinical trial for bexotegrast in patients with primary sclerosing cholangitis (PSC).
• The 320 mg dose group met its primary and secondary endpoints, demonstrating that bexotegrast was well-tolerated and its plasma concentrations increased with dose.
• There was no dose relationship for adverse events.
• Exploratory efficacy endpoints showed a reduction in liver fibrosis markers (ELF score and PRO-C3 levels) in bexotegrast-treated patients compared to placebo at Week 12.
• Bexotegrast-treated patients also showed stabilization of alkaline phosphatase (ALP) levels, while the placebo group showed an increase at Week 12.
• MRI imaging indicated improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
• The trial enrolled 121 patients with PSC, with 27 patients in the 320 mg active arm and 9 new patients added to the pooled placebo arm.
• The 320 mg dose group will continue until all patients have been treated for at least 24 weeks, with final data expected in mid-2024.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a clinical trial, with no significant safety concerns and promising efficacy signals. The language used is optimistic and forward-looking, suggesting a positive outlook for the company and its drug candidate.

Positives

• The 320 mg dose of bexotegrast was well-tolerated with no drug-related severe or serious adverse events.
• Bexotegrast showed a reduction in liver fibrosis markers, ELF and PRO-C3, compared to placebo.
• MRI imaging indicated improved hepatocyte function and bile flow with bexotegrast.
• Adverse events of pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.
• The trial used an enrichment strategy to enroll patients with suspected moderate to severe liver fibrosis.
• Bexotegrast demonstrated statistically significant reductions in the Itch Numerical Rating Scale relative to placebo at Week 12.

Negatives

• The document does not explicitly state any negative results, but it does mention that most treatment-emergent adverse events were mild or moderate in severity and consistent with PSC disease symptoms.

Risks

• The document mentions risks related to the development and commercialization of product candidates, including delays in clinical trials.
• There are risks associated with reliance on third parties for development operations.
• The company faces risks inherent in the drug development process, including the accuracy of expense and timing estimates.
• The company may require additional financing.
• There are risks related to obtaining and maintaining intellectual property protection for product candidates.

Future Outlook

The company plans to share the data with regulatory authorities to discuss the potential path to registration. The 320 mg dose group will continue until all patients have been treated for at least 24 weeks, with final data expected in mid-2024.

Management Comments

• Eric Lefebvre, M.D., Chief Medical Officer of Pliant, stated that the results build on the favorable safety and tolerability data for bexotegrast.
• Eric Lefebvre also noted that the treatment effects of bexotegrast are manifested across multiple endpoints, suggesting its potential to impact PSC.
• Kris V. Kowdley MD, Director, Liver Institute Northwest, said that the results present a strong rationale for further study of bexotegrast in patients with PSC.

Industry Context

The announcement is significant as there are currently no FDA or EMA-approved therapies for PSC, highlighting a high unmet need for new therapeutic options. The positive results for bexotegrast could position it as a potential treatment for this rare and progressive liver disease.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies or projects.
• However, it does mention that the INTEGRIS-PSC trial is the first randomized clinical trial to use an enrichment strategy to enroll patients with suspected moderate to severe liver fibrosis based on liver stiffness measure, ELF score or historical liver biopsy.
• The document references published studies on the use of ELF score and PRO-C3 as prognostic markers in liver disease, suggesting that the trial is using established metrics.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results.
• Patients with PSC may benefit from the development of a new treatment option.
• The company's employees may be motivated by the progress of the clinical trial.
• Regulatory authorities will be involved in the potential path to registration.

Next Steps

• The company plans to share the data with regulatory authorities to discuss the potential path to registration.
• The 320 mg dose group will continue until all patients have been treated for at least 24 weeks, with final data expected in mid-2024.
• The company will host a conference call and webcast to discuss the update.

Key Dates

Keywords

bexotegrast, primary sclerosing cholangitis, PSC, liver fibrosis, clinical trial, INTEGRIS-PSC, ELF score, PRO-C3, hepatocyte function, bile flow, fibrotic diseases, PLN-74809